

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Galen Hospital Alaska, Inc. dba Alaska Regional Hospital</p> <p>2. 2801 DeBarr Road Anchorage, AK 99508</p>		<p>In accordance with letter dated February 5, 2021,</p>	<p>4. Expiration Date: January 31, 2026</p>
		<p>3. License No.: 50-18244-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-14720 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Cesium-137 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed Sources (Medi-Physics, Inc. dba GE Healthcare (formerly Amersham), Model CDC.T1 (J Series tube source))</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1.5 curies total</p> <p>D. 450 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p>

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 50-18244-01

Docket or Reference No.:  
030-14720

Amendment No. 45

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Iodine-125 permitted by 10 CFR 35.400	E. Sealed Sources (Bard Brachytherapy, Inc., Model STM1251; Best Medical International, Inc., Model 2300 Series; IsoAid, LLC, Model IAI-125A; Theragenics Corporation, Model AgX100; I25.S06)	E. 30 millicuries total	E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed Sources (Best Medical International, Inc, Model 2300 Series; IsoAid, LLC, Model IAPd-103A; Theragenics Corporation, Model 200)	F. 30 millicuries total	F. For any manual brachytherapy procedure permitted by 10 CFR 35.400.
G. Strontium-90 permitted by 10 CFR 35.400	G. Sealed Sources (GE Healthcare (formerly Amersham), Model SIA.20)	G. 90 millicuries total	G. For storage only. The medical use of this sealed source is not authorized.
H. Yttrium-90 permitted by 10 CFR 35.1000	H. Microspheres (Current manufacturer as listed in the Sealed Source and Device Registry NR-1490-D-101-S, Model TheraSphere® Glass Microsphere)	H. 3 curies total	H. TheraSphere® for permanent brachytherapy using delivery system as listed in the Sealed Source and Device Registry.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 50-18244-01

Docket or Reference No.:  
030-14720

Amendment No. 45

CONDITIONS

10. Licensed material shall be used or stored only at the licensee's facilities located at 2801 DeBarr Road, Anchorage, Alaska, 99508.
11. The Radiation Safety Officer (RSO) for this license is Ryan Shea.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for the material and medical uses indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u>                                                                                       |
|-------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Dirk C. Bringhurst, M.D.                  | 35.100; 35.200; Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries |
| Richard Chung, M.D.                       | 35.300; 35.400                                                                                                |
| Matthew V. Cronin, M.D.                   | 35.100; 35.200                                                                                                |
| Daniel Andrew Davignon, Jr., D.O.         | 35.100; 35.200; Oral administration of sodium iodide I-131                                                    |
| Chris T. Glenn, M.D.                      | 35.100; 35.200; 35.300                                                                                        |
| Scott A. Harman, M.D.                     | 35.100; 35.200; 35.300                                                                                        |
| Julee K. Holayter, M.D.                   | 35.100; 35.200; 35.300                                                                                        |
| Aaron S. Kusano, M.D.                     | 35.300                                                                                                        |
| John P. Lubisich, M.D.                    | 35.100; 35.200; Oral administration of sodium iodide I-131                                                    |
| Andrew Moran, M.D.                        | 35.100; 35.200                                                                                                |
| William P. Perry, M.D.                    | Oral administration of sodium iodide I-131, 35.1000 only Yttrium-90 TheraSphere®                              |
| Jason Savikko, D.O.                       | Oral administration of sodium iodide I-131                                                                    |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 50-18244-01

Docket or Reference No.:  
030-14720

Amendment No. 45

Authorized User (M.D., D.O., etc.)

Lawrence P. Wood, M.D.

Material and Use

35.100; 35.200; Oral administration of sodium iodide I-131

13. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26 and applicable guidance updates for 10 CFR 35.1000 uses. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Application dated January 31, 2005 (ML050470499)
  - B. Letter dated September 26, 2006 (ML070250358)
  - C. Letter dated August 28, 2007 (ML072820029)
  - D. Letter dated August 9, 2010 (ML102710598)
  - E. Letter dated December 8, 2016 with enclosures (ML16355A226)
  - F. Letter dated March 28, 2017 with enclosures (ML17100A950)
  - G. E-mail dated April 11, 2017 with enclosures (ML17102B285)
  - H. Letter dated May 5, 2017 with enclosures (ML17143A442)
  - I. Letter dated August 9, 2017 (ML17221A279)

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 50-18244-01

Docket or Reference No.:  
030-14720

Amendment No. 45

J. Letter dated May 8, 2018 (ML18155A526)

K. Letter dated September 9, 2020 (ML20255A071)

L. Delegation of authority dated February 5, 2021 (ML21041A391)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 17, 2021

By: \_\_\_\_\_

Roberto J. Torres  
Region IV